Skip to main content

Table 1 Patients’ characteristics

From: Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy

  Monotherapy Boost Total p value
(n = 155) (n = 63) (n = 218)
Age (year)     
mean ± SD 68.1 ± 6.6 70.3 ± 6.2 68.7 ± 6.5 0.023 §
PSA at diagnosis (ng/mL)     
mean ± SD 7.2 ± 2.4 12.5 ± 6.1 8.7 ± 4.5 < 0.001 §
10 or less 139 22 161  
10-20 16 34 50  
greater than 20 0 7 7 < 0.001
biopsy Gleason score     
6 or less 111 22 133  
7 44 32 76  
8-10 0 9 9 < 0.001
clinical T stage     
T1c 99 32 131  
T2a 51 19 70  
T2b 5 6 11  
T2c 0 6 6 < 0.001
neoadjuvant/adjuvant ADT     
none 112 37 149  
neoadjuvant (+) 42 18 60  
adjuvant (+) 0 5 5  
both 1 3 4 0.001
IPSS at baseline     
mean ± SD 8.7 ± 6.9 7.2 ± 5.6 8.3 ± 6.6 0.107 §
Follow-up period (month)     
mean ± SD 44.2 ± 14.9 38.3 ± 16.2 42.5 ± 15.5 0.011 §
  1. Chi-square test and §t-test.